아시아태평양의 세포 및 유전자 치료 제조 서비스 시장 예측(-2030년) : 지역별 분석 - 유형별, 적응증별, 용도별, 최종사용자별

The Asia Pacific cell and gene therapy manufacturing services market is expected to grow from US$ 1,007.42 million in 2022 to US$ 3,613.18 million by 2030. It is estimated to grow at a CAGR of 17.3% from 2022 to 2030.

Automation of Cell and Gene Therapy Manufacturing Services Drives Asia Pacific Cell and Gene Therapy Manufacturing Services Market

Incorporating automation in cell and gene therapy manufacturing would lead to a reduced risk of contamination, improved consistency, and decreased cost of production. Lonza Cocoon and the CliniMACS Prodigy system from Miltenyi are a few of the devices available in the market to enable automation. These products have been designed to enable the automation of most sequential unit operations for a CAR-T process within a single system. The rising demand for cell and gene therapies has shifted the production of cell and gene therapy products from a small-volume process to a large-volume process worldwide. In addition to the increasing research activities, the evolution of cell and gene therapy from an academic and clinical setting to mass production and commercialization has propelled the demand for automation in commercial manufacturing. In July 2020, Thermo Fisher Scientific Inc. and Lyell Immunopharma partnered to develop and manufacture processes to design effective cell therapies for cancer patients. Under this partnership, the companies aim to improve the capability of T-cells and support the development of an integrated current good manufacturing practice (cGMP) compliant platform (system and software), along with reagents, consumables, and instruments. Thus, automation is emerging as a new trend in the Asia Pacific cell and gene therapy manufacturing services market.

Asia Pacific Cell and Gene Therapy Manufacturing Services Market Overview

Asia Pacific region comprises of China, Japan, India, Australia, South Korea, and Rest of Asia Pacific countries. The Asia Pacific region is one of the leading regions in the field of cell and gene therapy, with several countries which are involved in the investing in research and development of these therapies. Japan is one of the leaders in the Asia Pacific region when it comes to cell and gene therapies. In 2014, Japan was the first country to approve a cell therapy product, a treatment for macular degeneration. Several other cell and gene therapies have been approved in the country since then, including the CAR-T for leukemia and lymphoma.

China is the first country to approve a gene therapy in 2003, since then cell and gene therapy development has advanced rapidly worldwide, and their therapeutic potential has soared. China's government has conducted several regulatory reforms to promote normative development of cell and gene therapies. According to a study published in Nature in 2021, China is home to more than 50% of all cell therapy trials across the world. Currently, China has nearly 400 ongoing CAR-T trials centered on hematology and oncology and solid tumors. Cell therapy in China is entering a new era with the approval of Fosun Kite's Yescarta and JW Therapeutics' Relma-cel in 2021 from the National Medical Products Administration (NMPA). Due to lower costs and larger patient populations, several multinational companies have moved to the region to take advantage of these factors.

Asia Pacific Cell and Gene Therapy Manufacturing Services Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Cell and Gene Therapy Manufacturing Services Market Segmentation

The Asia Pacific cell and gene therapy manufacturing services market is segmented into type, indication, application, end user, and country.

Based on type, the Asia Pacific cell and gene therapy manufacturing services market is bifurcated into cell therapy and gene therapy. In 2022, the cell therapy segment registered a larger share in the Asia Pacific cell and gene therapy manufacturing services market. The cell therapy segment is further segmented into autologous and allogenic. The gene therapy segment is further segmented into viral and non-viral vector.

Based on indication, the Asia Pacific cell and gene therapy manufacturing services market is segmented into cancer, orthopedics, and others. In 2022, the cancer segment registered the largest share in the Asia Pacific cell and gene therapy manufacturing services market.

Based on application, the Asia Pacific cell and gene therapy manufacturing services market is segmented into clinical manufacturing and commercial manufacturing. In 2022, the commercial manufacturing segment registered the largest share in the Asia Pacific cell and gene therapy manufacturing services market.

Based on end user, the Asia Pacific cell and gene therapy manufacturing services market is bifurcated into pharmaceutical and biotechnology companies and contract research organization (CROs). In 2022, the pharmaceutical and biotechnology companies segment registered a larger share in the Asia Pacific cell and gene therapy manufacturing services market.

Based on country, the Asia Pacific cell and gene therapy manufacturing services market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. In 2022, China registered the largest share in the Asia Pacific cell and gene therapy manufacturing services market.

Catalent Inc, Charles River Laboratories International Inc, FUJIFILM Holdings Corp, Lonza Group AG, Merck KgaA, Nikon Corp, Takara Bio Inc, Thermo Fisher Scientific Inc, and WuXi AppTec Co Ltd are some of the leading companies operating in the Asia Pacific cell and gene therapy manufacturing services market.

Table Of Contents

1. Introduction

• 1.1 The Insight Partners Research Report Guidance
• 1.2 Market Segmentation

2. Executive Summary

• 2.1 Key Insights

3. Research Methodology

• 3.1 Coverage
• 3.2 Secondary Research
• 3.3 Primary Research

4. Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Key Industry Dynamics

• 4.1 Key Market Drivers:
  • 4.1.1 Increase in Number of Approval of Cell and Gene Therapies
  • 4.1.2 Increasing Popularity of Outsourcing Cell and Gene Therapy Manufacturing
• 4.2 Market Restraints
  • 4.2.1 High Cost of Cell and Gene Therapy Manufacturing
• 4.3 Market Opportunities
  • 4.3.1 Strategic Initiatives by Companies
• 4.4 Future Trends
  • 4.4.1 Automation of Cell and Gene Therapy Manufacturing Services
• 4.5 Impact Analysis:

5. Cell and Gene Therapy Manufacturing Services Market - Asia Pacific Market Analysis

• 5.1 Asia Pacific Cell and Gene Therapy Manufacturing Services Market Revenue (US$ Mn), 2022 - 2030

6. Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - by Type

• 6.1 Overview
• 6.2 Asia Pacific Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Type 2022 & 2030 (%)
• 6.3 Cell Therapy
  • 6.3.1 Overview
  • 6.3.2 Cell Therapy: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    • 6.3.2.1 Autologous
      • 6.3.2.1.1 Overview
      • 6.3.2.1.2 Autologous: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    • 6.3.2.2 Allogenic
      • 6.3.2.2.1 Overview
      • 6.3.2.2.2 Allogenic: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
• 6.4 Gene Therapy
  • 6.4.1 Overview
  • 6.4.2 Gene Therapy: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    • 6.4.2.1 Viral Vector
      • 6.4.2.1.1 Overview
      • 6.4.2.1.2 Viral Vector: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
    • 6.4.2.2 Non-Viral Vector
      • 6.4.2.2.1 Overview
      • 6.4.2.2.2 Non-Viral Vector: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

7. Asia Pacific Cell and Gene Therapy Manufacturing Services Market Analysis and Forecasts to 2030 - by Indication

• 7.1 Overview
• 7.2 Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication 2022 & 2030 (%)
• 7.3 Cancer
  • 7.3.1 Overview
  • 7.3.2 Cancer: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
• 7.4 Orthopedics
  • 7.4.1 Overview
  • 7.4.2 Orthopedics: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
• 7.5 Others
  • 7.5.1 Overview
  • 7.5.2 Others: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - by Application

• 8.1 Overview
• 8.2 Asia Pacific Cell and Gene Therapy Manufacturing Services Market Revenue Share, by Application 2022 & 2030 (%)
• 8.4 Clinical Manufacturing
  • 8.4.1 Overview
  • 8.4.2 Clinical Manufacturing: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
• 8.5 Commercial Manufacturing
  • 8.5.1 Overview
  • 8.5.2 Commercial Manufacturing: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - by End User

• 9.1 Overview
• 9.2 Asia Pacific Cell and Gene Therapy Manufacturing Services Market Revenue Share, by End User 2022 & 2030 (%)
• 9.4 Pharmaceutical and Biotechnology Companies
  • 9.4.1 Overview
  • 9.4.2 Pharmaceutical & Biotechnology Companies: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
• 9.5 Contract Research Organizations (CROs)
  • 9.5.1 Overview
  • 9.5.2 Contract Research Organizations (CROs): Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)

10. Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 - Country Analysis

• 10.1 Overview
  • 10.1.1 Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Region, 2022 & 2030 (%)
    • 10.1.1.1 China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.1.1.1.1 China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
      • 10.1.1.1.1.1 China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
      • 10.1.1.1.1.2 China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
      • 10.1.1.1.2 China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
      • 10.1.1.1.3 China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
      • 10.1.1.1.4 China: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
    • 10.1.1.2 Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.1.1.2.1 Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
      • 10.1.1.2.1.1 Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
      • 10.1.1.2.1.2 Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
      • 10.1.1.2.2 Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
      • 10.1.1.2.3 Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
      • 10.1.1.2.4 Japan: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
    • 10.1.1.3 India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.1.1.3.1 India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
      • 10.1.1.3.1.1 India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
      • 10.1.1.3.1.2 India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
      • 10.1.1.3.2 India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
      • 10.1.1.3.3 India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
      • 10.1.1.3.4 India: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
    • 10.1.1.4 Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.1.1.4.1 Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
      • 10.1.1.4.1.1 Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
      • 10.1.1.4.1.2 Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
      • 10.1.1.4.2 Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
      • 10.1.1.4.3 Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
      • 10.1.1.4.4 Australia: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
    • 10.1.1.5 South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.1.1.5.1 South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
      • 10.1.1.5.1.1 South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
      • 10.1.1.5.1.2 South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
      • 10.1.1.5.2 South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
      • 10.1.1.5.3 South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
      • 10.1.1.5.4 South Korea: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)
    • 10.1.1.6 Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Revenue and Forecast to 2030 (US$ Million)
      • 10.1.1.6.1 Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Type, 2020-2030 (US$ Million)
      • 10.1.1.6.1.1 Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Cell Therapy, 2020-2030 (US$ Million)
      • 10.1.1.6.1.2 Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Gene Therapy, 2020-2030 (US$ Million)
      • 10.1.1.6.2 Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Indication, 2020-2030 (US$ Million)
      • 10.1.1.6.3 Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by Application, 2020-2030 (US$ Million)
      • 10.1.1.6.4 Rest of Asia Pacific: Asia Pacific Cell and Gene Therapy Manufacturing Services Market, by End User, 2020-2030 (US$ Million)

11. Asia Pacific Cell and Gene Therapy Manufacturing Services Market - Industry Landscape

• 11.1 Overview
• 11.2 Growth Strategies in Asia Pacific Cell and Gene Therapy Manufacturing Services Market
• 11.3 Organic Growth Strategies
  • 11.3.1 Overview
• 11.4 Inorganic Growth Strategies
  • 11.4.1 Overview

12. Company Profiles

• 12.1 Thermo Fisher Scientific Inc
  • 12.1.1 Key Facts
  • 12.1.2 Business Description
  • 12.1.3 Products and Services
  • 12.1.4 Financial Overview
  • 12.1.5 SWOT Analysis
  • 12.1.6 Key Developments
• 12.2 Merck KGaA
  • 12.2.1 Key Facts
  • 12.2.2 Business Description
  • 12.2.3 Products and Services
  • 12.2.4 Financial Overview
  • 12.2.5 SWOT Analysis
  • 12.2.6 Key Developments
• 12.3 Charles River Laboratories International Inc
  • 12.3.1 Key Facts
  • 12.3.2 Business Description
  • 12.3.3 Products and Services
  • 12.3.4 Financial Overview
  • 12.3.5 SWOT Analysis
  • 12.3.6 Key Developments
• 12.4 Lonza Group AG
  • 12.4.1 Key Facts
  • 12.4.2 Business Description
  • 12.4.3 Products and Services
  • 12.4.4 Financial Overview
  • 12.4.5 SWOT Analysis
  • 12.4.6 Key Developments
• 12.5 WuXi AppTec Co Ltd?
  • 12.5.1 Key Facts
  • 12.5.2 Business Description
  • 12.5.3 Products and Services
  • 12.5.4 Financial Overview
  • 12.5.5 SWOT Analysis
  • 12.5.6 Key Developments
• 12.6 Catalent Inc
  • 12.6.1 Key Facts
  • 12.6.2 Business Description
  • 12.6.3 Products and Services
  • 12.6.4 Financial Overview
  • 12.6.5 SWOT Analysis
  • 12.6.6 Key Developments
• 12.7 Takara Bio Inc
  • 12.7.1 Key Facts
  • 12.7.2 Business Description
  • 12.7.3 Products and Services
  • 12.7.4 Financial Overview
  • 12.7.5 SWOT Analysis
  • 12.7.6 Key Developments
• 12.8 Nikon Corp
  • 12.8.1 Key Facts
  • 12.8.2 Business Description
  • 12.8.3 Products and Services
  • 12.8.4 Financial Overview
  • 12.8.5 SWOT Analysis
  • 12.8.6 Key Developments
• 12.9 FUJIFILM Holdings Corp
  • 12.9.1 Key Facts
  • 12.9.2 Business Description
  • 12.9.3 Products and Services
  • 12.9.4 Financial Overview
  • 12.9.5 SWOT Analysis
  • 12.9.6 Key Developments